Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: So here is a question I've seen asked many times. It's one that now has....

According to Ronran there was no winner or loser in the settlement in the EDOT.

Many here are accepting that there is no more coming in from the J's settlement ever based on information in the letters to shareholders. If this is true why would TPL grant a free license to the J's when it appeared the markman was so strongly in our favor? Why would TPL request that the A trial be transferred to EDOT if we did so poorly there? Why are any of us still here if the main reason for being here is the MMP patents? I would say the NDA for the J's settlement has worked to perfection. Even true long time believers in the patents are doubting there strength and are buying the idea that the J's were let off the hook because our position was weak.

None of us know what the business resolution between TPL and the J's is and probably never will. The wording in the shareholders letters can be misleading if you take it at face value IMO. Common sence tells me with what we all learned after the markman ruling was that the patents are strong and TPL was in the drivers seat during the negotiations. The only thing I can come up with is centered around the USPTO re-examination. Am I all excited and getting my hopes up? no. If investors want to believe there is no more coming from the J's then great believe all you want. I'm still sticking to a contingency payment centered on the USPTO decision and I don't know why this is so upsetting to some shareholders.

All the best,

Steve

Share
New Message
Please login to post a reply